• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Final analysis of randomized phase II study optimizing melphalan, prednisolone, bortezomib in multiple myeloma (JCOG1105).

作者信息

Maruyama Dai, Iida Shinsuke, Machida Ryunosuke, Kusumoto Shigeru, Fukuhara Noriko, Yamauchi Nobuhiko, Miyazaki Kana, Yoshimitsu Makoto, Kuroda Junya, Tsukamoto Norifumi, Tsujimura Hideki, Usuki Kensuke, Yamauchi Takahiro, Utsumi Takahiko, Mizuno Ishikazu, Takamatsu Yasushi, Nagata Yasuyuki, Ota Shuichi, Ohtsuka Eiichi, Hanamura Ichiro, Suzuki Yasuhiro, Yoshida Shinichiro, Yamasaki Satoshi, Suehiro Youko, Kamiyama Yutaro, Fukuhara Suguru, Tsukasaki Kunihiro, Nagai Hirokazu

机构信息

Department of Hematology Oncology, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan.

Department of Hematology and Oncology, Nagoya City University Hospital, Nagoya, Japan.

出版信息

Cancer Sci. 2022 Sep;113(9):3267-3270. doi: 10.1111/cas.15484. Epub 2022 Jul 31.

DOI:10.1111/cas.15484
PMID:35909244
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9459263/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e36e/9459263/26868ce4e18b/CAS-113-3267-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e36e/9459263/8c35f9ad1f62/CAS-113-3267-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e36e/9459263/26868ce4e18b/CAS-113-3267-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e36e/9459263/8c35f9ad1f62/CAS-113-3267-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e36e/9459263/26868ce4e18b/CAS-113-3267-g001.jpg

相似文献

1
Final analysis of randomized phase II study optimizing melphalan, prednisolone, bortezomib in multiple myeloma (JCOG1105).优化美法仑、泼尼松龙、硼替佐米治疗多发性骨髓瘤的随机II期研究（JCOG1105）的最终分析
Cancer Sci. 2022 Sep;113(9):3267-3270. doi: 10.1111/cas.15484. Epub 2022 Jul 31.
2
Randomised phase II study to optimise melphalan, prednisolone, and bortezomib in untreated multiple myeloma (JCOG1105).随机 II 期研究旨在优化未经治疗的多发性骨髓瘤中的马法兰、泼尼松和硼替佐米（JCOG1105）。
Br J Haematol. 2021 Feb;192(3):531-541. doi: 10.1111/bjh.16878. Epub 2020 Jun 24.
3
Prognostic impact of the UK Myeloma Research Alliance Risk Profile in transplant-ineligible patients with multiple myeloma who received a melphalan, prednisolone, and bortezomib regimen: A supplementary analysis of JCOG1105.英国骨髓瘤研究联盟风险评估对接受美法仑、泼尼松龙和硼替佐米方案治疗的不适于移植的多发性骨髓瘤患者的预后影响：JCOG1105的补充分析
Hematol Oncol. 2023 Aug;41(3):590-593. doi: 10.1002/hon.3103. Epub 2022 Nov 30.
4
Single response assessment of transplant-ineligible multiple myeloma: a supplementary analysis of JCOG1105 (JCOG1105S1).不适合移植的多发性骨髓瘤的单次反应评估：JCOG1105（JCOG1105S1）的补充分析。
Jpn J Clin Oncol. 2021 Jul 1;51(7):1059-1066. doi: 10.1093/jjco/hyab066.
5
The clinical effectiveness and cost-effectiveness of bortezomib and thalidomide in combination regimens with an alkylating agent and a corticosteroid for the first-line treatment of multiple myeloma: a systematic review and economic evaluation.硼替佐米联合来那度胺与烷化剂和皮质类固醇在多发性骨髓瘤一线治疗中的临床疗效和成本效益：系统评价和经济评估。
Health Technol Assess. 2011 Dec;15(41):1-204. doi: 10.3310/hta15410.
6
Autologous haematopoietic stem-cell transplantation versus bortezomib-melphalan-prednisone, with or without bortezomib-lenalidomide-dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02/HO95): a multicentre, randomised, open-label, phase 3 study.自体造血干细胞移植对比硼替佐米-美法仑-泼尼松（联合或不联合硼替佐米-来那度胺-地塞米松巩固治疗）以及来那度胺维持治疗用于新诊断的多发性骨髓瘤（EMN02/HO95）：一项多中心、随机、开放标签的3期研究
Lancet Haematol. 2020 Jun;7(6):e456-e468. doi: 10.1016/S2352-3026(20)30099-5. Epub 2020 Apr 30.
7
Combined chemotherapy versus melphalan and prednisolone for treatment of myelomatosis.联合化疗与美法仑和泼尼松治疗骨髓瘤的对比研究
Lancet. 1992 May 30;339(8805):1353-4.
8
Daratumumab Plus Bortezomib, Melphalan, and Prednisone Versus Bortezomib, Melphalan, and Prednisone in Transplant-Ineligible Newly Diagnosed Multiple Myeloma: Frailty Subgroup Analysis of ALCYONE.达雷妥尤单抗联合硼替佐米、美法仑和泼尼松与硼替佐米、美法仑和泼尼松在不适合移植的新诊断多发性骨髓瘤中的应用：ALCYONE 研究体弱亚组分析。
Clin Lymphoma Myeloma Leuk. 2021 Nov;21(11):785-798. doi: 10.1016/j.clml.2021.06.005. Epub 2021 Jun 18.
9
Daratumumab: A Review in Combination Therapy for Transplant-Ineligible Newly Diagnosed Multiple Myeloma.达雷妥尤单抗：在不适合移植的新诊断多发性骨髓瘤联合治疗中的应用评价。
Drugs. 2019 Mar;79(4):447-454. doi: 10.1007/s40265-019-01080-6.
10
Bortezomib improves survival in rare myeloma.硼替佐米可提高罕见骨髓瘤患者的生存率。
Lancet Oncol. 2016 Jun;17(6):e227. doi: 10.1016/S1470-2045(16)30129-2. Epub 2016 May 6.

引用本文的文献

1
Lipidomic profiling of plasma from patients with multiple myeloma receiving bortezomib: an exploratory biomarker study of JCOG1105 (JCOG1105A1).接受硼替佐米的多发性骨髓瘤患者血浆的脂质组学分析：JCOG1105（JCOG1105A1）的探索性生物标志物研究
Cancer Chemother Pharmacol. 2025 Jan 24;95(1):29. doi: 10.1007/s00280-025-04752-1.
2
Romidepsin-induced durable remission for relapsed nodal peripheral T-cell lymphoma with T follicular helper phenotype after allogeneic hematopoietic cell transplantation.罗米地辛诱导异基因造血细胞移植后复发结外 T 细胞淋巴瘤伴滤泡辅助 T 细胞表型的持久缓解
Int J Hematol. 2023 Aug;118(2):292-298. doi: 10.1007/s12185-023-03561-7. Epub 2023 Feb 20.

本文引用的文献

1
Randomised phase II study to optimise melphalan, prednisolone, and bortezomib in untreated multiple myeloma (JCOG1105).随机 II 期研究旨在优化未经治疗的多发性骨髓瘤中的马法兰、泼尼松和硼替佐米（JCOG1105）。
Br J Haematol. 2021 Feb;192(3):531-541. doi: 10.1111/bjh.16878. Epub 2020 Jun 24.
2
Bortezomib plus melphalan and prednisone compared with melphalan and prednisone in previously untreated multiple myeloma: updated follow-up and impact of subsequent therapy in the phase III VISTA trial.硼替佐米联合美法仑和泼尼松与美法仑和泼尼松治疗未经治疗的多发性骨髓瘤的比较：III 期 VISTA 试验的更新随访结果和后续治疗的影响。
J Clin Oncol. 2010 May 1;28(13):2259-66. doi: 10.1200/JCO.2009.26.0638. Epub 2010 Apr 5.